Trial reportArthritis & rheumatology (Hoboken, N.J.)2025
Effect of Long-Term Voclosporin Treatment on Renal Histology in Patients With Active Lupus Nephritis With Repeat Renal Biopsies.
Trial report in Arthritis & rheumatology (Hoboken, N.J.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Disease modification in lupus nephritis: towards a pathophysiology-based treatment paradigm.Nature reviews. Nephrology · 2026Review
- Does Voclosporin Redefine Lupus Nephritis Treatment? A Tri-Focal View of Efficacy, Safety, and Costs.Current medical science · 2026Review
- Systematic Review of Trial Design and End Points in Lupus Nephritis.Kidney international reports · 2026Article
- Early antiproteinuric effect of voclosporin in patients with LN in a real-life setting: preliminary results from the VoRLiSS (Voclosporin in Real Life Setting Study) experience.Rheumatology (Oxford, England) · 2026Observational
- Kidney adverse events associated with calcineurin inhibitors: a real-world study based on the FAERS database and network pharmacology.Frontiers in medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
objectiveThis study characterized the impact of voclosporin on kidney histology in patients with lupus nephritis (LN) who had protocolized repeat kidney biopsies in the AURORA clinical trials.
methodsPatients were randomized to voclosporin or placebo treatment for up to 3 years; all patients received mycophenolate mofetil and low-dose glucocorticoids. Patients had baseline kidney biopsies within 6 months before study start and repeat biopsies after approximately 18 months of study treatment. The revised National Institutes of Health indices for LN activity and chronicity (CI) were calculated in addition to a semiquantitative assessment of vascular and tubular lesions.
resultsSixteen patients in the voclosporin group and 10 patients in the control group had both baseline and repeat kidney biopsies. Patient clinical characteristics were similar at baseline. In the voclosporin group, most (n = 13) patients had pure class IV lesions (pure class V, n = 1; mixed, n = 2). In the control group, three patients had pure class IV (pure class III, n = 3; pure class V, n = 1; mixed, n = 3). Most of the voclosporin-treated patients had no change in CI (n = 8) or a change no greater than 2 (n = 6); control-treated patients also had no change in CI (n = 3) or a change no greater than 2 (n = 6). No trends in vascular lesions or tubular compartment changes were observed.
conclusionOutcomes from this small subgroup show that exposure to study treatment was not associated with nephrotoxicity based on histopathologic evaluation after 18 months. These data are reassuring and further contribute to the safety profile of voclosporin for the treatment of adults with active LN.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.